Molecular preselection of pediatric patients with solid tumors treated with tyrosine kinase inhibitors

Molecular background of tumors should be taken into account when using TKIs. The current molecular pre-selection criteria are insufficient and need to be improved.

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2026-01-29
DOI
https://doi.org/10.1080/14796694.2026.2621651
Primary Topic
Chronic Myeloid Leukemia Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Molecular preselection of pediatric patients with solid tumors treated with tyrosine kinase inhibitors

Tomáš Fazekaš, Ján Klimas, Peter Šišovský, Nikola Gejgusova
Future Oncology
Chronic Myeloid Leukemia Treatments
article

Molecular preselection of pediatric patients with solid tumors treated with tyrosine kinase inhibitors

Tomáš Fazekaš, Ján Klimas, Peter Šišovský, Nikola Gejgusova
article en

Abstract

Molecular background of tumors should be taken into account when using TKIs. The current molecular pre-selection criteria are insufficient and need to be improved.

Future OncologyVol. 22(4)
University Hospital Brno (CZ), Comenius University Bratislava (SK)
Openalex Percentile: Top 77%
Chronic Myeloid Leukemia Treatments
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Molecular preselection of pediatric patients with solid tumors treated with tyrosine kinase inhibitors — Tomáš Fazekaš, Ján Klimas, et al. · Future Oncology (2026) | TGRS Research Map | TGRS